AaronDavidGoldbergMDPhD

Hematologic Oncology

Assistant Attending Physician

Overview of Dr. Goldberg

Dr. Aaron Goldberg is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Sloan Kettering Cancer Center. He received his medical degree from Weill Cornell Medicine and has been in practice 7 years. He is one of 62 doctors at Memorial Sloan Kettering Cancer Center and one of 62 doctors at Memorial Sloan Kettering Cancer Center who specialize in Hematology. He has more than 50 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(256) 712-2991

Fax+1 929-321-8153

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Brigham and Women's HospitalResidency, Internal Medicine, 2011 - 2014
Weill Cornell MedicineClass of 2011, MD
Rockefeller UniversityPhD, Epigenetics and Chromatin Biology, 2004 - 2010

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2014 - 2026
NJ State Medical License 2018 - 2025
NC State Medical License 2020 - 2022
ME State Medical License 2020 - 2021
MA State Medical License 2014 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

ASH Fellow Scholar Award in Clinical Research American Society of Hematology, 2018
ASCO Young Investigator Award Conquer Cancer Foundation of the American Society of Clinical Oncology, 2017
Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Oncology/Hematology Clinical Research Award Pfizer, 2017
Chief Hematology Fellow Memorial Sloan Kettering Cancer Center, 2017
Join now to see all

Clinical Trials

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2016 Feb 01
Terminated
Phase 1
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Recruiting
Phase 3
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) Start of enrollment: 2018 Oct 03
Withdrawn
Phase 1, Phase 2
APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies Start of enrollment: 2019 Dec 13
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

HMA/VEN treatment modifications and associated outcomes in-mutant AML.
Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav K Gupta, P Dayand Borge
Leukemia & Lymphoma. 2024-10-14
Y220C mutations in patients with myeloid malignancies.
Georgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi, Alex Bataller, Aaron D Goldberg
Leukemia & Lymphoma. 2024-10-01
1 citations
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.
Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, Yiwen Liu, Guillaume Berton
Blood Advances. 2024-09-24

Abstracts/Posters

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...
Aaron D Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...
Aaron D Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy
Aaron D Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism
Aaron D Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all